ORIC Pharmaceuticals (Nasdaq: ORIC) announced the initiation of its Himalayas-1 global Phase 3 registrational trial evaluating rinzimetostat in patients with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE